Edesa Biotech Shares Outstanding 2013-2024 | EDSA

Edesa Biotech shares outstanding from 2013 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.

Edesa Biotech Shares Outstanding 2013-2024 | EDSA

Edesa Biotech shares outstanding from 2013 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$178.9B
Regeneron Pharmaceuticals (REGN)$125.5B
Vertex Pharmaceuticals (VRTX)$122.4B
Gilead Sciences (GILD)$104.4B
Bristol Myers Squibb (BMY)$100.8B
CSL (CSLLY)$96.8B
GSK (GSK)$87.9B
Alnylam Pharmaceuticals (ALNY)$35.1B
Argenex SE (ARGX)$31.6B
Biogen (BIIB)$28.8B
BioNTech SE (BNTX)$27.5B
Moderna (MRNA)$26.9B
Illumina (ILMN)$20.9B
BeiGene (BGNE)$19.2B
Genmab (GMAB)$17.3B
BioMarin Pharmaceutical (BMRN)$13.5B
Vaxcyte (PCVX)$13B
Exact Sciences (EXAS)$12.8B
Incyte (INCY)$12.6B
Insmed (INSM)$12.5B
Bio-Techne Corp (TECH)$12.1B
Sarepta Therapeutics (SRPT)$11.9B
QIAGEN (QGEN)$10.4B
Bio-Rad Laboratories (BIO.B)$9.1B
Legend Biotech (LEGN)$9.1B
Roivant Sciences (ROIV)$8.9B
Ascendis Pharma (ASND)$8.7B
Repligen (RGEN)$8B
Halozyme Therapeutics (HALO)$7.9B
Intra-Cellular Therapies (ITCI)$7.9B